CLLS ▼ -0.6% - Cellectis S.A. $CLLS - Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company Cellectis announced a strategic transformation to focus on in vivo gene editing, shifting its business direction away from its prior approach. The stock declined 0.6% on the news, suggesting investors may be digesting the operational and financial implications of this strategic pivot. 14-SEP-2026 02:40 AM ET